Why Receptos Inc. Shares Briefly Popped
Receptos shares jump following the company's fourth-quarter earnings report. Here's what investors should really have their eyes on.
A Closer Look at Multiple Sclerosis Treatments in 2014: BIIB, NVS, TEVA, SNY, RCPT
In 2014, the market for multiple sclerosis treatments could shift in favor of newer oral treatments. Let’s take a closer look at how Biogen, Novartis, Teva, Sanofi, and Receptos will fit into this changing market.
A Year-End Look at 3 High-Flying Biotech IPOs of 2013: PETX, RCPT, STML
Aratana Therapeutics Inc., Receptos Inc., and Stemline Therapeutics Inc. are three biotech IPOs of 2013 that are finishing the year with strong gains. Can they continue soaring into 2014?
This Week in Biotech: Part 2
With 11 noteworthy biotech events this week, Part 2 of this weekly series looks at six clinical updates that amazed investors, including a mid-stage cancer trial that sent shares of one company up 74% while a large pharmaceutical company chalked up another failure.
Why Receptos Inc. Shares Soared
Receptos shares vault higher after getting the A-OK from the independent data monitoring committee.